Literature DB >> 27062904

Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis.

Jaclyn R Stonebraker1, Chee Y Ooi2, Rhonda G Pace3, Harriet Corvol4, Michael R Knowles3, Peter R Durie5, Simon C Ling6.   

Abstract

BACKGROUND & AIMS: Liver disease is the third leading cause of death in patients with cystic fibrosis (CF), but features of patients with CF, severe liver disease, and portal hypertension have not been characterized fully.
METHODS: We performed a retrospective analysis of data from 561 patients with CF (63% male, 99% with pancreatic insufficiency), liver disease (hepatic parenchymal abnormalities consistent with cirrhosis, confirmed by imaging), and portal hypertension (esophageal varices, portosystemic collaterals, or splenomegaly), with no alternate causes of liver disease. All patients were enrolled in the Genetic Modifier Study of Severe CF Liver Disease at 76 international centers, from January 1999 through July 2013.
RESULTS: Male patients were diagnosed with liver disease at a younger age than female patients (10 vs 11 y; P = .01). Splenomegaly was observed in 99% of patients and varices in 71%. Levels of liver enzymes were near normal in most patients. Thrombocytopenia affected 70% of patients and was more severe in patients with varices (88 × 10(9)/L vs 145 × 10(9)/L; P < .0001). Ninety-one patients received liver transplants (16%), at a median age of 13.9 years. Compared with patients who did not receive liver transplants, patients who received liver transplants had lower platelet counts (78 × 10(9)/L vs 113 × 10(9)/L; P < .0001), higher international normalized ratios (P < .0001), and lower levels of albumin (P = .0002). The aminotransferase to platelet ratio index (APRi) and fibrosis index based on 4 factor (FIB-4) values were higher than the diagnostic thresholds for CF liver disease in 96% and in 90% of patients, respectively. Patients who received liver transplants or who had varices had higher APRi and FIB-4 values than patients who did not.
CONCLUSIONS: In patients with CF, severe liver disease develops early in childhood (approximately 10 years of age), and is more common in boys than in girls. Patients with varices and those who receive liver transplants have more abnormal platelet counts and APRi and FIB-4 scores.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  ALT; CFLD; INR; Phenotype; Portal Pressure

Mesh:

Year:  2016        PMID: 27062904      PMCID: PMC4955685          DOI: 10.1016/j.cgh.2016.03.041

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  29 in total

1.  Closing the gaps in pediatric laboratory reference intervals: a CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children.

Authors:  David A Colantonio; Lianna Kyriakopoulou; Man Khun Chan; Caitlin H Daly; Davor Brinc; Allison A Venner; Maria D Pasic; David Armbruster; Khosrow Adeli
Journal:  Clin Chem       Date:  2012-02-27       Impact factor: 8.327

Review 2.  Sexual dimorphism in the liver.

Authors:  A K Roy; B Chatterjee
Journal:  Annu Rev Physiol       Date:  1983       Impact factor: 19.318

3.  Epidemiology of liver disease in cystic fibrosis: a longitudinal study.

Authors:  Thierry Lamireau; Sylvie Monnereau; Steven Martin; Jacques-Edouard Marcotte; Maria Winnock; Fernando Alvarez
Journal:  J Hepatol       Date:  2004-12       Impact factor: 25.083

Review 4.  Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis.

Authors:  Chee Y Ooi; Peter R Durie
Journal:  J Cyst Fibros       Date:  2012-06-02       Impact factor: 5.482

5.  Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease.

Authors:  Tamara N Pereira; Peter J Lewindon; Jeffery L Smith; Therese L Murphy; Douglas J Lincoln; Ross W Shepherd; Grant A Ramm
Journal:  J Hepatol       Date:  2004-10       Impact factor: 25.083

6.  SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease.

Authors:  Jeffrey B Schwimmer; Winston Dunn; Gregory J Norman; Perrie E Pardee; Michael S Middleton; Nanda Kerkar; Claude B Sirlin
Journal:  Gastroenterology       Date:  2010-01-11       Impact factor: 22.682

7.  Outcome in patients with cystic fibrosis liver disease.

Authors:  Marion Rowland; Cliona Gallagher; Charles G Gallagher; Risteárd Ó Laoide; Gerard Canny; Anne Marie Broderick; Jennifer Drummond; Peter Greally; Dubhfeasa Slattery; Leslie Daly; Noel G McElvaney; Billy Bourke
Journal:  J Cyst Fibros       Date:  2014-06-07       Impact factor: 5.482

8.  High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.

Authors:  Keith D Lindor; Kris V Kowdley; Velimir A C Luketic; M Edwyn Harrison; Timothy McCashland; Alex S Befeler; Denise Harnois; Roberta Jorgensen; Jan Petz; Jill Keach; Jody Mooney; Carol Sargeant; Julie Braaten; Tamara Bernard; Debra King; Ellen Miceli; Jeff Schmoll; Tanya Hoskin; Prabin Thapa; Felicity Enders
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

9.  Genetic modifiers of liver disease in cystic fibrosis.

Authors:  Jaclyn R Bartlett; Kenneth J Friedman; Simon C Ling; Rhonda G Pace; Scott C Bell; Billy Bourke; Giuseppe Castaldo; Carlo Castellani; Marco Cipolli; Carla Colombo; John L Colombo; Dominique Debray; Adriana Fernandez; Florence Lacaille; Milan Macek; Marion Rowland; Francesco Salvatore; Christopher J Taylor; Claire Wainwright; Michael Wilschanski; Dana Zemková; William B Hannah; M James Phillips; Mary Corey; Julian Zielenski; Ruslan Dorfman; Yunfei Wang; Fei Zou; Lawrence M Silverman; Mitchell L Drumm; Fred A Wright; Ethan M Lange; Peter R Durie; Michael R Knowles
Journal:  JAMA       Date:  2009-09-09       Impact factor: 56.272

Review 10.  Intestinal obstruction syndromes in cystic fibrosis: meconium ileus, distal intestinal obstruction syndrome, and constipation.

Authors:  Hubert P J van der Doef; Freddy T M Kokke; Cornelis K van der Ent; Roderick H J Houwen
Journal:  Curr Gastroenterol Rep       Date:  2011-06
View more
  25 in total

1.  Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity.

Authors:  Christopher Koh; Sasan Sakiani; Pallavi Surana; Xiongce Zhao; Jason Eccleston; David E Kleiner; David Herion; T Jake Liang; Jay H Hoofnagle; Milica Chernick; Theo Heller
Journal:  Hepatology       Date:  2017-06-26       Impact factor: 17.425

Review 2.  Liver disease in patients with cystic fibrosis.

Authors:  Natasha Kamal; Pallavi Surana; Christopher Koh
Journal:  Curr Opin Gastroenterol       Date:  2018-05       Impact factor: 3.287

3.  Genetic variation in CFTR and modifier loci may modulate cystic fibrosis disease severity.

Authors:  Alekh Paranjapye; Manon Ruffin; Ann Harris; Harriet Corvol
Journal:  J Cyst Fibros       Date:  2019-11-14       Impact factor: 5.482

4.  Liver Ultrasound Patterns in Children With Cystic Fibrosis Correlate With Noninvasive Tests of Liver Disease.

Authors:  Simon C Ling; Wen Ye; Daniel H Leung; Oscar M Navarro; Alexander Weymann; Wikrom Karnsakul; A Jay Freeman; John C Magee; Michael R Narkewicz
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-09       Impact factor: 2.839

5.  Role of transient elastography and APRI in the assessment of pediatric cystic fibrosis liver disease.

Authors:  Jessica P Woolfson; Richard A Schreiber; Shraavan Raveendran; Mark Chilvers; Collin Barker; Orlee R Guttman
Journal:  Can Liver J       Date:  2021-02-24

Review 6.  Cystic fibrosis liver disease: A condition in need of structured transition and continuity of care.

Authors:  Julian Hercun; Fernando Alvarez; Catherine Vincent; Marc Bilodeau
Journal:  Can Liver J       Date:  2019-08-27

7.  Heterogeneous Liver on Research Ultrasound Identifies Children with Cystic Fibrosis at High Risk of Advanced Liver Disease: Interim Results of a Prospective Observational Case-Controlled Study.

Authors:  Marilyn J Siegel; A Jay Freeman; Wen Ye; Joseph J Palermo; Jean P Molleston; Shruti M Paranjape; Janis Stoll; Daniel H Leung; Prakash Masand; Boaz Karmazyn; Roger Harned; Simon C Ling; Oscar M Navarro; Wikrom Karnsakul; Adina Alazraki; Sarah Jane Schwarzenberg; Frank Glen Seidel; Alex Towbin; Estella M Alonso; Jennifer L Nicholas; Karen F Murray; Randolph K Otto; Averell H Sherker; John C Magee; Michael R Narkewicz
Journal:  J Pediatr       Date:  2020-02-12       Impact factor: 4.406

8.  Variceal Hemorrhage and Adverse Liver Outcomes in Patients With Cystic Fibrosis Cirrhosis.

Authors:  Wen Ye; Michael R Narkewicz; Daniel H Leung; Wikrom Karnsakul; Karen F Murray; Estella M Alonso; John C Magee; Sarah Jane Schwarzenberg; Alexander Weymann; Jean P Molleston
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-01       Impact factor: 2.839

9.  Reply.

Authors:  Christopher Koh; Sasan Sakiani; Theo Heller
Journal:  Hepatology       Date:  2018-01-01       Impact factor: 17.425

10.  Clinical use of shear-wave elastography for detecting liver fibrosis in children and adolescents with cystic fibrosis.

Authors:  Steven Levitte; Lori W Lee; Jared Isaacson; Evan J Zucker; Carlos Milla; Richard A Barth; Zachary M Sellers
Journal:  Pediatr Radiol       Date:  2021-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.